Open access
Open access
Powered by Google Translator Translator

RCT | Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to TNFα inhibitors

19 Jan, 2023 | 14:05h | UTC

Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE) – The Lancet

Related Study: Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL) – The Lancet

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.